Active PsA | TREMFYA® (guselkumab) HCP

IN ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)

1 IN 2 PATIENTS EXPERIENCED COMPLETE RESOLUTION OF ENTHESITIS AT WEEK 241,2

ENTHESITIS

View Study Design

POOLED DATA FROM DISCOVER 1 AND DISCOVER 2: RESOLUTION OF ENTHESITIS (LEI SCORE=0) AT WEEKS 24 AND 52 (NRI ANALYSIS)*†‡

DISCOVER 2 ONLY: RESOLUTION OF ENTHESITIS (LEI SCORE=0) AT WEEK 100 (NRI ANALYSIS)*

LEI=Leeds Enthesitis Index.

*Among patients with enthesitis LEI score >0 at baseline.

Through Week 24, patients were considered to be nonresponders after meeting treatment failure criteria: discontinued study agent due to any reason, terminated study participation for any reason, initiated or increased the dose of DMARDs or oral corticosteroids over baseline for PsA, or initiated protocol-prohibited medications/therapies for PsA. After Week 24, treatment failure rules were not applied.

Patients with missing data were considered nonresponders.

§After Week 24, patients and healthcare providers knew that all patients were on TREMFYA® (open label with a blinded dosing interval), which may have affected the results.

||The prespecified as-observed analyses at Week 52 and Week 100 are not shown.

IN ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)
NEARLY 6 OUT OF 10 PATIENTS EXPERIENCED COMPLETE RESOLUTION OF DACTYLITIS AT WEEK 241,2

DACTYLITIS

View Study Design

POOLED DATA FROM DISCOVER 1 AND DISCOVER 2: 
RESOLUTION OF DACTYLITIS (DACTYLITIS SCORE=0) 
AT WEEKS 24 AND 52 (NRI ANALYSIS)†‡​**

DISCOVER 2 ONLY: RESOLUTION OF DACTYLITIS (DACTYLITIS SCORE=0) AT WEEK 100 (NRI ANALYSIS)**

†​Through Week 24, patients were considered to be nonresponders after meeting treatment failure criteria: discontinued study agent due to any reason, terminated study participation for any reason, initiated or increased the dose of DMARDs or oral corticosteroids over baseline for PsA, or initiated protocol-prohibited medications/therapies for PsA. After Week 24, treatment failure rules were not applied.

Patients with missing data were considered nonresponders.

§After Week 24, patients and healthcare providers knew that all patients were on TREMFYA® (open label with blinded dosing interval), which may have affected the results.

||The prespecified as-observed analyses at Week 52 and Week 100 are not shown.

**Among patients with dactylitis at baseline.

 

References: 1. Mease PJ, Rahman P, Gottlieb AB, et al; DISCOVER-2 Study Group. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126-1136. doi:10.1016/S0140-6736(20)30263-4. 2. Data on file. Janssen Biotech, Inc.